FindTrial
Sign In

A Study of the Efficacy and Safety of Tirofiban Versus Alteplase in the Treatment of Acute Mild Ischemic Stroke

A Study of the Efficacy and Safety of Tirofiban Versus Alteplase in the Treatment of Acute Mild Ischemic Stroke

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500106107
Enrollment
Unknown
Registered
2025-07-17
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke

Interventions

Tirofiban Group:None
Alteplase Group:None

Sponsors

China-Japan Union Hospital of Jilin University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with cerebral infarction, the diagnostic criteria meet the "Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2023 Edition" and the NIHSS score is <=5; 2. Age 18-80 years old; 3. Computed tomography or magnetic resonance imaging at the time of admission; 4. Start treatment within 4.5 hours of the onset of stroke symptoms.

Exclusion criteria

Exclusion criteria: 1. Interventional treatment for this cerebral infarction; 2. Baseline mRS score > 2 points; 3. Previous history of intracerebral hemorrhage or clear indication for anticoagulation; 4. No follow-up results.

Design outcomes

Primary

MeasureTime frame
Modified Rankin Scale score;—

Secondary

MeasureTime frame
NIHSS score;New stroke or other vascular events;All-cause mortality rate;—

Countries

China

Contacts

Public ContactZhongxin Xu

China-Japan Union Hospital of Jilin University

zxxu@jlu.edu.cn+86 176 8435 0927

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026